Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 3/2021

01-03-2021 | Endoscopy | Review

Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis

Authors: Saurabh Chandan, Babu P. Mohan, Shahab R. Khan, Antonio Facciorusso, Daryl Ramai, Lena L. Kassab, Neil Bhogal, Ravishankar Asokkumar, Gortrand Lopez-Nava, Stephanie McDonough, Douglas G. Adler

Published in: Obesity Surgery | Issue 3/2021

Login to get access

Abstract

Intragastric balloon (IGB) therapy has shown efficacy in weight loss but its role in NAFLD remains unknown. We conducted a systematic review and meta-analysis to evaluate the efficacy of IGB in NAFLD. Meta-analysis was performed to estimate the pooled proportion of patients with improvement in steatosis as determined by imaging and histology following IGB placement. Nine studies were included in our analysis. Four hundred forty-two IGBs were placed. Improvement in steatosis was seen in 79.2% of patients and NAS in 83.5% of patients, and HOMA-IR score improved in 64.5% of patients. A reduction in liver volume by CT scan was noticed in 93.9% of patients undergoing IGB placement. IGB is an effective and safe short-term therapeutic modality for patients with NAFLD.
Appendix
Available only for authorised users
Literature
1.
Younossi ZM et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530.e1.PubMedCrossRef
2.
Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.PubMedCrossRef
3.
Vernon G, Baranova A, Younossi Z. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.PubMedCrossRef
4.
Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;178(1):38–45.PubMedPubMedCentralCrossRef
5.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.PubMedCrossRef
6.
Kleiner DE, Brunt EM, van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.PubMedCrossRef
7.
Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107(4):1103–9.PubMedCrossRef
8.
Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8.PubMedCrossRef
9.
Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286–92.PubMedCrossRef
10.
Westerouen Van Meeteren MJ, Drenth JP, Tjwa ET. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29(2):117–23.PubMedCrossRef
11.
12.
Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46.PubMedCrossRef
13.
Vilar-Gomez E et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378.e5.PubMedCrossRef
14.
Lee Y et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–1060.e11.PubMedCrossRef
15.
Weiner JP, Goodwin SM, Chang HY, et al. Impact of bariatric surgery on health care costs of obese persons: a 6-year follow-up of surgical and comparison cohorts using health plan data. JAMA surgery. 2013;148(6):555–61.PubMedCrossRef
16.
Gulliford MC, Charlton J, Prevost T, et al. Costs and outcomes of increasing access to bariatric surgery: cohort study and cost-effectiveness analysis using electronic health records. Value Health. 2017;20(1):85–92.PubMedPubMedCentralCrossRef
17.
Dayyeh BKA, Edmundowicz S, Thompson CC. Clinical practice update: expert review on endoscopic bariatric therapies. Gastroenterology. 2017;152(4):716–29.PubMedCrossRef
18.
Frutos MD, Morales MD, Luján J, et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg. 2007;17(2):150–4.PubMedCrossRef
19.
Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71(6):927–33.PubMedCrossRef
20.
Folini L, Veronelli A, Benetti A, et al. Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. Acta Diabetol. 2014;51(3):361–8.PubMedCrossRef
21.
Bazerbachi F, Vargas EJ, Rizk M, et al. Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020;
22.
Nguyen V et al. Outcomes following serial intragastric balloon therapy for obesity and nonalcoholic fatty liver disease in a single centre. Can J Gastroenterol Hepatol. 2017;2017:4697194.PubMedPubMedCentralCrossRef
23.
Lee Y-M, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76(4):756–60.PubMedCrossRef
24.
Ricci G, Bersani G, Rossi A, et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18(11):1438–42.PubMedCrossRef
25.
Sekino Y, Imajo K, Sakai E, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med. 2011;50(21):2449–55.PubMedCrossRef
26.
Takihata M, Nakamura A, Aoki K, et al. Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients. Obes Res Clin Pract. 2014;8(4):e331–8.PubMedCrossRef
27.
Stroup DF et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–12.PubMedCrossRef
28.
Agnihotri A et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol. 2018;16(7):1081–1088.e1.PubMedCrossRef
29.
Donadio F, Sburlati LF, Masserini B, et al. Metabolic parameters after BioEnterics intragastric balloon placement in obese patients. J Endocrinol Investig. 2009;32(2):165–8.CrossRef
30.
Raftopoulos I, Giannakou A. The Elipse Balloon, a swallowable gastric balloon for weight loss not requiring sedation, anesthesia or endoscopy: a pilot study with 12-month outcomes. Surg Obes Relat Dis. 2017;13(7):1174–82.PubMedCrossRef
31.
Stimac D et al. Intragastric balloon treatment for obesity: results of a large single center prospective study. Obes Surg. 2011;21(5):551–5.PubMedCrossRef
32.
Tai CM, Lin HY, Yen YC, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg. 2013;23(12):2068–74.PubMedCrossRef
33.
Vargas EJ et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol. 2018;16(7):1073–1080.e1.PubMedPubMedCentralCrossRef
34.
Zerrweck C, Maunoury V, Caiazzo R, et al. Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients. Obes Surg. 2012;22(5):777–82.PubMedCrossRef
35.
Sullivan S, Swain J, Woodman G, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis. 2018;14(12):1876–89.PubMedCrossRef
36.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
37.
38.
Sutton AJ, A.K., Jones DR, et al, Methods for meta-analysis in medical research. 2000, New York: J. Wiley.
39.
40.
Mohan BP, Adler DG. Heterogeneity in systematic review and meta-analysis: how to read between the numbers. Gastrointest Endosc. 2019;89(4):902–3.PubMedCrossRef
41.
42.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication Bias in meta-analysis. Biometrics. 2000;56(2):455–63.PubMedCrossRef
43.
Rothstein HR, Sutton AJ, and Borenstein M, Publication bias in meta-analysis: prevention, assessment and adjustments. 2006: John Wiley & Sons.
44.
Espinet-Coll E et al. Bariatric restrictive endoscopy procedures (one-year IB and ESG-Apollo) in the treatment of fatty liver disease (NAFLD). Initial experience. Obes Surg. 2019;29(5 Supplement):536.
45.
Abu Dayyeh BK et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies Prepared by. Gastrointest Endosc. 2015;82(3):425–438.e5.PubMedCrossRef
46.
Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - executive summary. Endocr Pract. 2019;25(12):1346–59.PubMed
47.
Panel CDC. Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991;115(12):956–61.CrossRef
48.
Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11.PubMedCrossRef
49.
Padwal R, Klarenbach S, Wiebe N, et al. Bariatric surgery: a systematic review of the clinical and economic evidence. J Gen Intern Med. 2011;26(10):1183–94.PubMedPubMedCentralCrossRef
50.
Campos GM, Khoraki J, Browning MG, et al. Changes in utilization of bariatric surgery in the United States from 1993 to 2016. Ann Surg. 2020;271(2):201–9.PubMedCrossRef
51.
Peterson, K., Anderson J., Boundy E., Ferguson L., Erickson K., Rapid evidence review of bariatric surgery in super obesity (BMI ≥ 50 kg/m. J Gen Intern Med, 2017. 32(Suppl 1): p. 56–64.
52.
Gottig S et al. Analysis of safety and efficacy of intragastric balloon in extremely obese patients. Obes Surg. 2009;19(6):677–83.PubMedCrossRef
53.
Shannon A, Alkhouri N, Carter-Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr. 2011;53(2):190–5.PubMedPubMedCentralCrossRef
54.
Lee SS, Park SH, Kim HJ, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010;52(4):579–85.PubMedCrossRef
55.
van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256(1):159–68.PubMedCrossRef
56.
Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239(1):105–12.PubMedCrossRef
57.
Gutierrez-Buey G, Núñez-Córdoba JM, Llavero-Valero M, et al. Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes? Eur J Intern Med. 2017;41:74–8.PubMedCrossRef
Metadata
Title
Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis
Authors
Saurabh Chandan
Babu P. Mohan
Shahab R. Khan
Antonio Facciorusso
Daryl Ramai
Lena L. Kassab
Neil Bhogal
Ravishankar Asokkumar
Gortrand Lopez-Nava
Stephanie McDonough
Douglas G. Adler
Publication date
01-03-2021
Publisher
Springer US
Published in
Obesity Surgery / Issue 3/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-05084-0

Other articles of this Issue 3/2021

Obesity Surgery 3/2021 Go to the issue

Original Contributions

Barrett’s Oesophagus and Bariatric/Metabolic Surgery—IFSO 2020 Position Statement

Letter to the Editor

IFSO Endoscopy Committee Position Statement on the Practice of Bariatric Endoscopy During the COVID-19 Pandemic

Original Contributions

K-Wire Retractor, a Trocar-Free Liver Retraction Technique in Bariatric Surgery

New Concept

A Rodent Model of Jejunal-Ileal Loop Bipartition (JILB): a Novel Malabsorptive Operation

Original Contributions

Cardiovascular Risk Factors Following Vertical Sleeve Gastrectomy in Black Americans Compared with White Americans

Review

Metabolic Effects of Endoscopic Duodenal Mucosal Resurfacing: a Systematic Review and Meta-analysis